Literature DB >> 18189231

Obesity and screening PSA levels among men undergoing an annual physical exam.

Andrew Rundle1, Alfred I Neugut.   

Abstract

BACKGROUND: Prior reports suggest that obesity is inversely associated with screening prostate-specific antigen (PSA) levels and may reduce screening sensitivity.
METHODS: We evaluated data on 10,623 men screened for prostate cancer during an annual physical examination program administered by EHE International, Inc., between 1/1/2004 and 6/30/2006. Of these, 3,623 men returned for additional physical exams during this period. We used multivariate linear regression analyses to determine whether higher BMI was inversely associated with PSA, and whether BMI, or change in BMI, was associated with change in PSA levels over time. We also developed a theoretical model for the effect of obesity on PSA levels in which increased plasma volume in the obese dilutes PSA levels.
RESULTS: After control for age and race/ethnicity, higher BMI was associated with lower PSA levels; men with a BMI > or =40 had a geometric mean PSA level 0.14 ng/ml lower than men with a BMI <25 (P < 0.001). Prospectively, BMI at initial screening and change in BMI over 2 years were not associated with change in PSA or PSA velocity. Our theoretical model accurately predicted observed PSA levels and suggests that a screening PSA of 4.0 ng/ml in normal weight and overweight men corresponds to 3.5 ng/ml in obese men and 3.1 ng/ml in morbidly obese men.
CONCLUSION: Across the study population, increased BMI was significantly inversely associated with lower PSA. Based on a theoretical model in which increased plasma volume in the obese dilutes PSA levels we propose new cut-points for a positive screening test. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18189231     DOI: 10.1002/pros.20704

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  18 in total

1.  Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.

Authors:  Andrew Rundle; Yun Wang; Sudha Sadasivan; Dhananjay A Chitale; Nilesh S Gupta; Deliang Tang; Benjamin A Rybicki
Journal:  Prostate       Date:  2017-03-27       Impact factor: 4.104

2.  Cancer Progress and Priorities: Prostate Cancer.

Authors:  Kevin H Kensler; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02       Impact factor: 4.254

3.  Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening.

Authors:  Yuanyuan Liang; Donna P Ankerst; Michael Sanchez; Robin J Leach; Ian M Thompson
Journal:  Urology       Date:  2010-08-24       Impact factor: 2.649

4.  Trends and co-trends of prostate-specific antigen and body mass index in a screened population.

Authors:  Donna P Ankerst; Brad H Pollock; Yuanyuan Liang; Nidzara Dizdarevic; Sergiy Kyrylenko; Andreas Boeck; Ian M Thompson; Robin Leach
Journal:  Urology       Date:  2011-05-07       Impact factor: 2.649

5.  The effect of demographic and clinical factors on the relationship between BMI and PSA levels.

Authors:  Jonathan L Wright; Daniel W Lin; Janet L Stanford
Journal:  Prostate       Date:  2011-03-22       Impact factor: 4.104

6.  The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy.

Authors:  Lionel L Bañez; Simone Albisinni; Stephen J Freedland; Andrea Tubaro; Cosimo De Nunzio
Journal:  World J Urol       Date:  2012-07-31       Impact factor: 4.226

7.  Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate.

Authors:  Andrew Rundle; Michelle Jankowski; Oleksandr N Kryvenko; Deliang Tang; Benjamin A Rybicki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-23       Impact factor: 4.254

8.  Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy?

Authors:  Karim Chamie; Stephanie Oberfoell; Lorna Kwan; Jessica Labo; John T Wei; Mark S Litwin
Journal:  Urology       Date:  2013-03-07       Impact factor: 2.649

9.  Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.

Authors:  Aruna V Sarma; James Hotaling; Rodney L Dunn; Patricia A Cleary; Barbara H Braffett; Catherine Kim; Catherine Martin; William Herman; Patricia Gatcomb; Alan M Jacobson; Sarah K Holt; Hunter Wessells
Journal:  J Urol       Date:  2014-09-11       Impact factor: 7.450

10.  A Review on the Clinical Utility of PSA in Cancer Prostate.

Authors:  Mohan Adhyam; Anish Kumar Gupta
Journal:  Indian J Surg Oncol       Date:  2012-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.